Dr. Patrick Soon-Shiong: The Billionaire Surgeon’s Quest for Immunotherapy 2.0, Curing Cancer with NK Cells, and the Future of the LA Times

Dr. Patrick Soon-Shiong is a world-renowned physician, surgeon, scientist, and inventor who has spent over 30 years dedicated to understanding the fundamental biology behind life-threatening diseases. In this episode, we delve into the extraordinary career of a man often described as the richest doctor in Los Angeles, whose life journey began in apartheid-era South Africa and led him to become a transformative force in biotechnology, artificial intelligence, and media.

The Architect of Next-Generation Medicine Dr. Soon-Shiong’s medical breakthroughs have consistently challenged the status quo. He first gained global recognition for inventing Abraxane, a groundbreaking protein nanoparticle chemotherapy that has achieved blockbuster status for the treatment of breast, lung, and pancreatic cancer. His surgical career is equally historic, having performed the first whole-organ pancreas transplant at UCLA and the world’s first encapsulated islet cell transplant to treat Type 1 diabetes.

We explore his current mission at ImmunityBio: a paradigm shift he calls "Immunotherapy 2.0". This approach focuses on harnessing the body's natural immune system—specifically Natural Killer (NK) cells—to outsmart the "immuno-evasion" tactics of cancer. A major milestone in this quest was reached in 2024 when the FDA approved Anktiva, a first-in-class IL-15 receptor superagonist for the treatment of non-muscle invasive bladder cancer.

A Multi-Industry Ecosystem: NantWorks and AI Dr. Soon-Shiong’s vision extends beyond individual drugs to a massive ecosystem known as NantWorks, designed to integrate semiconductor technology, supercomputing, and augmented intelligence to revolutionize healthcare delivery. From deploying AI-based machine learning for digital pathology to identifying aggressive cancer subtypes with near-human accuracy, Dr. Soon-Shiong is building a "panomic" framework for the future of personalized medicine.

The 100-Year Project: The Los Angeles Times In 2018, Dr. Soon-Shiong expanded his influence into the civic sphere by acquiring the Los Angeles Times. He views the newspaper as a "100-year project" vital to the survival of democracy, attempting to modernize its digital infrastructure while navigating the complex realities of modern journalism.

Navigating Controversy and Legal Challenges Despite his achievements, Dr. Soon-Shiong’s career is shadowed by significant controversy. This episode provides an objective look at the allegations of self-dealing, breach of fiduciary duty, and "catch and kill" schemes that have led to high-stakes litigation, including a $125 million arbitration award involving the drug Cynviloq. We also discuss recent newsroom friction at the LA Times over editorial independence and the implementation of AI-powered "bias meters".

A Life Built on Curiosity and Resilience From his early days dissecting frogs with his father's surgical tools to his time performing stem cell experiments for NASA, Dr. Soon-Shiong’s story is defined by a "relentless pursuit" of discovery. Join us as we examine the legacy of a man who describes himself as a "billionaire by accident" but remains, at his core, a doctor committed to treating patients at scale.